Theriva Biologics Reschedules Special Stockholder Meeting

Theriva Biologics ( (TOVX) ) has provided an announcement.

On December 15, 2025, Theriva Biologics was unable to convene its Special Meeting of Stockholders due to insufficient shares present to constitute a quorum. Consequently, the company will reschedule the meeting to seek approval for a warrant exercise proposal, as required under a warrant inducement agreement with institutional investors. This agreement mandates that Theriva Biologics continues to call stockholder meetings every 60 days until approval is obtained or the warrants are no longer outstanding.

The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics, Inc. operates in the biotechnology industry, focusing on the development of biologic therapies. The company is involved in creating innovative solutions to address unmet medical needs, with a market focus on advancing therapeutic options.

Average Trading Volume: 15,391,171

Technical Sentiment Signal: Strong Sell

Current Market Cap: $7.33M

Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.